SERA PROGNOSTICS, INC.

The company is a women's health company that uses its proprietary proteomics and bioinformatics platform and extensive data resources to improve maternal and neonatal health. It achieves this by discovering, developing, and selling blood-based biomarker tests and predictive analytic products and services. The company aims to provide crucial and actionable information to pregnant women, their doctors, and healthcare payers to enhance the pregnancy experience, improve health outcomes for mothers and newborns, and lower healthcare costs. The company combines proteomics and bioinformatics with thorough clinical testing, data, and economic analysis. This approach allows it to offer personalized, clinically relevant, and economically beneficial information to improve pregnancy outcomes. Globally, there are approximately 140 million births each year, with about 3.7 million births annually in the United States. An estimated 30% of these pregnancies are affected by complications such as preterm birth, preeclampsia, fetal growth restriction, stillbirth, hypertension of pregnancy, and gestational diabetes. The company believes that current methods for predicting adverse pregnancy outcomes are inadequate for timely and effective management of most high-risk pregnancies. Preterm birth is a significant health risk in the U.S., contributing to approximately 34% of newborn deaths. The 2025 March of Dimes Report Card gave the United States a D+ grade for preterm birth for the fourth consecutive year.